ADBiotech Balance Sheet Health
Financial Health criteria checks 3/6
ADBiotech has a total shareholder equity of ₩7.9B and total debt of ₩11.9B, which brings its debt-to-equity ratio to 150.1%. Its total assets and total liabilities are ₩22.9B and ₩15.0B respectively.
Key information
150.1%
Debt to equity ratio
₩11.91b
Debt
Interest coverage ratio | n/a |
Cash | ₩3.83b |
Equity | ₩7.93b |
Total liabilities | ₩14.97b |
Total assets | ₩22.90b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A179530's short term assets (₩8.7B) do not cover its short term liabilities (₩11.0B).
Long Term Liabilities: A179530's short term assets (₩8.7B) exceed its long term liabilities (₩4.0B).
Debt to Equity History and Analysis
Debt Level: A179530's net debt to equity ratio (101.8%) is considered high.
Reducing Debt: Insufficient data to determine if A179530's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A179530 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A179530 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 32.5% each year.